Moniuszko-Malinowska Anna, Czupryna Piotr, Zarębska-Michaluk Dorota, Tomasiewicz Krzysztof, Pancewicz Sławomir, Rorat Marta, Dworzańska Anna, Sikorska Katarzyna, Bolewska Beata, Lorenc Beata, Chciałowski Andrzej, Kozielewicz Dorota, Oczko-Grzesik Barbara, Szymanek-Pasternak Anna, Szetela Bartosz, Figlerowicz Magdalena, Rogalska Magdalena, Zaleska Izabela, Flisiak Robert
Department of Infectious Diseases and Neuroinfections, Medical University of Białystok, 15-085 Białystok, Poland.
Department of Infectious Diseases, Jan Kochanowski University, 25-369 Kielce, Poland.
J Clin Med. 2020 Dec 24;10(1):28. doi: 10.3390/jcm10010028.
Because the optimal treatment for COVID-19 is still unknown, it is important to explore every potential way of improving the chances of survival for COVID-19 patients. The aim of the study was to analyze the effectiveness of convalescent plasma on COVID-19 patients. The study population consisted of 78 patients diagnosed with COVID-19, selected from the SARSTer national database, who received convalescent plasma. The impact on clinical and laboratory parameters was assessed. A clinical improvement was observed in 62 (79%) patients, and 10 (13%) patients died from COVID-19. No side effects of the convalescent plasma treatment were observed. When plasma was administered earlier than 7 days from diagnosis, the total hospitalization time was shorter ( < 0.05). Plasma efficacy was inferior to remdesivir in endpoints such as the necessity and duration of oxygen therapy, the duration of hospitalization, and mortality rate, and inferior to other drugs in the case of the duration of hospitalization and the necessity of constant oxygen therapy, but comparable in most other measured endpoints. A comparison of a 30-day mortality rate in patients who received plasma and remdesivir (4/25, 16%) and who received only plasma (6/53, 11%) showed no significant difference. Convalescent plasma efficacy is inferior to remdesivir when treating COVID-19 patients but the addition of remdesivir to plasma does not improve the treatment effectiveness. In most endpoints, plasma was comparable to other treatment options. In our opinion, convalescent plasma may be used as a supportive treatment in COVID-19 patients because of the low frequency of adverse effects and availability, but must be given as early from the diagnosis as possible.
由于新冠病毒病（COVID-19）的最佳治疗方法仍不明确，探索提高COVID-19患者生存几率的每一种潜在方法非常重要。本研究的目的是分析康复期血浆对COVID-19患者的疗效。研究人群包括从SARS-CoV-2国家数据库中选取的78例确诊为COVID-19并接受康复期血浆治疗的患者。评估了其对临床和实验室参数的影响。62例（79%）患者临床症状改善，10例（13%）患者死于COVID-19。未观察到康复期血浆治疗的副作用。在诊断后7天内更早给予血浆时，总住院时间更短（P<0.05）。在诸如氧疗的必要性和持续时间、住院时间和死亡率等终点方面，血浆疗效不如瑞德西韦，在住院时间和持续吸氧必要性方面不如其他药物，但在大多数其他测量终点方面相当。接受血浆和瑞德西韦治疗的患者（4/25，16%）与仅接受血浆治疗的患者（6/53，11%）的30天死亡率比较无显著差异。治疗COVID-19患者时，康复期血浆疗效不如瑞德西韦，但在血浆中添加瑞德西韦并不能提高治疗效果。在大多数终点方面，血浆与其他治疗选择相当。我们认为，由于不良反应发生率低且易于获得，康复期血浆可作为COVID-19患者的支持性治疗方法，但必须在诊断后尽早给予。
